Literature DB >> 14577978

Nicotine metabolite ratio as a predictor of cigarette consumption.

Neal L Benowitz1, Ovide F Pomerleau, Cynthia S Pomerleau, Peyton Jacob.   

Abstract

The rate of nicotine metabolism is hypothesized to be a determinant of how much a person smokes. That is, rapid metabolizers would be expected to need more nicotine and, therefore, smoke more than slow metabolizers. Nicotine is metabolized extensively by the liver enzyme CYP2A6, primarily to cotinine. Cotinine is itself metabolized by CYP2A6 to 3'-hydroxycotinine (3-HC). The ratio of metabolite to parent (i.e., 3-HC:cotinine) would be expected to reflect CYP2A6 activity. We measured the ratio of 3-HC:cotinine in the urine of 72 smokers. This ratio was significantly correlated with the number of cigarettes smoked per day (r=.33, p=.005), though not with the Fagerström Test for Nicotine Dependence. This finding supports the hypothesis that the rate of nicotine metabolism is a determinant of the level of cigarette consumption and supports the use of the 3-HC:cotinine ratio as a noninvasive marker of nicotine metabolism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14577978     DOI: 10.1080/1462220031000158717

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  86 in total

1.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

Review 2.  Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.

Authors:  Cheyenne E Allenby; Kelly A Boylan; Caryn Lerman; Mary Falcone
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-12       Impact factor: 4.147

3.  Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism.

Authors:  Jacob G Dubroff; Robert K Doot; Mary Falcone; Robert A Schnoll; Riju Ray; Rachel F Tyndale; Arthur L Brody; Catherine Hou; Alexander Schmitz; Caryn Lerman
Journal:  J Nucl Med       Date:  2015-08-13       Impact factor: 10.057

4.  A link between adolescent nicotine metabolism and smoking topography.

Authors:  Eric T Moolchan; Craig S Parzynski; Maria Jaszyna-Gasior; Charles C Collins; Michelle K Leff; Debra L Zimmerman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-05       Impact factor: 4.254

5.  Differential success rates in racial groups: results of a clinical trial of smoking cessation among female prisoners.

Authors:  Karen L Cropsey; Michael F Weaver; Gloria D Eldridge; Gabriela C Villalobos; Al M Best; Maxine L Stitzer
Journal:  Nicotine Tob Res       Date:  2009-04-22       Impact factor: 4.244

6.  Status and Future Directions of Preclinical Behavioral Pharmacology in Tobacco Regulatory Science.

Authors:  Mark G LeSage; John R Smethells; Andrew C Harris
Journal:  Behav Anal (Wash D C)       Date:  2018-07-09

7.  Associations of cytochrome P450 oxidoreductase genetic polymorphisms with smoking cessation in a Chinese population.

Authors:  Huijie Li; Suyun Li; Qiang Wang; Chongqi Jia
Journal:  Hum Genet       Date:  2016-09-22       Impact factor: 4.132

8.  Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms.

Authors:  A Joseph Bloom; Timothy B Baker; Li-Shiun Chen; Naomi Breslau; Dorothy Hatsukami; Laura J Bierut; Alison Goate
Journal:  Hum Mol Genet       Date:  2013-09-17       Impact factor: 6.150

9.  Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial.

Authors:  Babalola Faseru; Nicole L Nollen; Matthew S Mayo; Ron Krebill; Won S Choi; Neal L Benowitz; Rachel F Tyndale; Kolawole S Okuyemi; Jasjit S Ahluwalia; Lisa Sanderson Cox
Journal:  Addict Behav       Date:  2012-11-29       Impact factor: 3.913

10.  Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype.

Authors:  Jeannette Zinggeler Berg; Jesse Mason; Angela J Boettcher; Dorothy K Hatsukami; Sharon E Murphy
Journal:  J Pharmacol Exp Ther       Date:  2009-09-28       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.